Columbus Macro LLC Acquires 769 Shares of Stryker Corporation $SYK

Key Points

• Columbus Macro LLC increased its holdings in Stryker Corporation by 6.2% during the 2nd quarter, acquiring an additional 769 shares, bringing its total to 13,107 shares valued at approximately $5.18 million.
• Several analysts have given Stryker a consensus rating of "Moderate Buy", with an average price target of $430.10, reflecting positive sentiment among market experts.
• Stryker recently reported earnings of $3.13 per share for the quarter, surpassing estimates, and announced a quarterly dividend of $0.84 per share, which will be payable on October 31st.

Columbus Macro LLC grew its holdings in shares of Stryker Corporation (NYSE:SYK - Free Report) by 6.2% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,107 shares of the medical technology company's stock after buying an additional 769 shares during the quarter. Columbus Macro LLC's holdings in Stryker were worth $5,186,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in SYK. Brighton Jones LLC lifted its position in Stryker by 15.4% during the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company's stock worth $1,643,000 after buying an additional 609 shares in the last quarter. Portside Wealth Group LLC increased its stake in shares of Stryker by 15.7% during the 1st quarter. Portside Wealth Group LLC now owns 789 shares of the medical technology company's stock worth $294,000 after purchasing an additional 107 shares during the last quarter. City Holding Co. increased its stake in shares of Stryker by 528.6% during the 1st quarter. City Holding Co. now owns 88 shares of the medical technology company's stock worth $33,000 after purchasing an additional 74 shares during the last quarter. Farther Finance Advisors LLC increased its stake in shares of Stryker by 7.9% during the 1st quarter. Farther Finance Advisors LLC now owns 6,799 shares of the medical technology company's stock worth $2,538,000 after purchasing an additional 496 shares during the last quarter. Finally, Harbor Capital Advisors Inc. acquired a new position in shares of Stryker during the 1st quarter worth about $1,840,000. 77.09% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. BTIG Research restated a "buy" rating on shares of Stryker in a research note on Monday, July 14th. Weiss Ratings restated a "buy (b-)" rating on shares of Stryker in a research note on Wednesday. Needham & Company LLC upped their price target on shares of Stryker from $442.00 to $448.00 and gave the company a "buy" rating in a research note on Friday, August 1st. Evercore ISI decreased their price target on shares of Stryker from $418.00 to $410.00 and set an "outperform" rating on the stock in a research note on Tuesday. Finally, Rothschild & Co Redburn assumed coverage on shares of Stryker in a research note on Thursday, September 18th. They issued a "neutral" rating and a $420.00 price target on the stock. Fifteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $430.10.

Stryker Stock Performance

NYSE SYK opened at $375.35 on Thursday. The company has a quick ratio of 1.06, a current ratio of 1.78 and a debt-to-equity ratio of 0.70. The company has a market capitalization of $143.50 billion, a P/E ratio of 49.72, a P/E/G ratio of 2.66 and a beta of 0.94. Stryker Corporation has a 12-month low of $329.16 and a 12-month high of $406.19. The firm has a 50-day moving average price of $380.99 and a two-hundred day moving average price of $378.83.

Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.13 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.07 by $0.06. The firm had revenue of $6.02 billion during the quarter, compared to the consensus estimate of $5.92 billion. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The business's revenue for the quarter was up 11.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.81 EPS. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. Analysts anticipate that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be issued a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date of this dividend is Tuesday, September 30th. Stryker's dividend payout ratio is 44.50%.

Insider Buying and Selling

In other news, Director Ronda E. Stryker sold 200,000 shares of the company's stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the completion of the sale, the director owned 3,222,108 shares of the company's stock, valued at approximately $1,212,962,556.60. This represents a 5.84% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Viju Menon sold 500 shares of the company's stock in a transaction that occurred on Monday, August 25th. The stock was sold at an average price of $390.61, for a total transaction of $195,305.00. Following the sale, the insider directly owned 12,511 shares of the company's stock, valued at approximately $4,886,921.71. This trade represents a 3.84% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 5.90% of the company's stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.